Delving into the Latest Updates on Fuzhou Changfuxing New Drug Development Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Neoplasms

Urogenital Diseases

Small molecule drug

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1
Herbal medicine	1

Top 5 Target	Count

5-HT1A receptor x 5-HT1B receptor x 5-HT1D receptor x 5-HT7 receptor x HTR3 x SERT	1

考察空腹及餐后条件下，健康研究参与者单次口服厦门恩成制药有限公司提供的受试制剂（VHDT口崩片，规格：10mg）和H.Lundbeck A/S持证的参比制剂（氢溴酸伏硫西汀片，商品名：心达悦®，规格：10mg）的药代动力学特征，评价两制剂间的生物等效性。

[Translation]

The pharmacokinetic characteristics of the test formulation (VHDT orally disintegrating tablets, strength: 10 mg) provided by Xiamen Encheng Pharmaceutical Co., Ltd. and the reference formulation (vortioxetine hydrobromide tablets, trade name: Xindayue®, strength: 10 mg) certified by H. Lundbeck A/S were examined under fasting and postprandial conditions to evaluate the bioequivalence between the two formulations.

Start Date10 Apr 2026

Sponsor / Collaborator

Fuzhou Changfuxing New Drug Development Co., Ltd.

[+1]

CTR20150274

/ Not yet recruitingPhase 2

靖宫颗粒与安慰剂平行对照治疗气滞血瘀证型子宫肌瘤的随机、双盲、多中心Ⅱb期临床试验

[Translation] A randomized, double-blind, multicenter phase Ⅱb clinical trial of Jinggong granules versus placebo in the treatment of uterine fibroids of Qi stagnation and blood stasis syndrome

通过多中心、随机、双盲、安慰剂平行对照研究，评价靖宫颗粒治疗气滞血瘀证型子宫肌瘤患者的有效性和安全性。

[Translation]

A multicenter, randomized, double-blind, placebo-controlled parallel study was conducted to evaluate the efficacy and safety of Jinggong Granule in the treatment of patients with uterine fibroids of Qi stagnation and blood stasis syndrome.

Start Date-

Sponsor / Collaborator

Fuzhou Changfuxing New Drug Development Co., Ltd.

100 Clinical Results associated with Fuzhou Changfuxing New Drug Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Fuzhou Changfuxing New Drug Development Co., Ltd.

Login to view more data

100 Deals associated with Fuzhou Changfuxing New Drug Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Fuzhou Changfuxing New Drug Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

NDA/BLA

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Jinggong Granules	Uterine Fibroids More	Phase 2
Vortioxetine Hydrobromide ( 5-HT1A receptor x 5-HT1B receptor x 5-HT1D receptor x 5-HT7 receptor x HTR3 x SERT )	Depressive Disorder More	Clinical